Highly-loaded protein nanocarriers prepared by Flash NanoPrecipitation with hydrophobic ion pairing

Ristroph, Kurt D.; Rummaneethorn, Paradorn; Johnson‐Weaver, Brandi T.; Staats, Herman F.; Prud'homme, Robert Krafft

doi:10.1016/j.ijpharm.2021.120397

Cited by 9 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…111 Kurt D Ristroph et al successfully encapsulated drug molecules within proteins by integrating Flash Nano Precipitation technology with the hydrophobic ion pairing technique, achieving an impressive loading efficiency of up to 46% for the proteins. 112 This reaffirms the outstanding loading capacity of protein nanocarriers, comparable to that of other biocarriers. Such high loading capabilities can curtail protein consumption, thereby lowering production costs and enhancing the production efficiency.…”

Section: Carrierssupporting

confidence: 53%

“…Certain proteins possess the ability to identify tumor marker molecules and target tumor cells even without the need for coupled ligands . Kurt D Ristroph et al successfully encapsulated drug molecules within proteins by integrating Flash Nano Precipitation technology with the hydrophobic ion pairing technique, achieving an impressive loading efficiency of up to 46% for the proteins . This reaffirms the outstanding loading capacity of protein nanocarriers, comparable to that of other biocarriers.…”

Section: Research Progress On Biological Drug Carriersmentioning

confidence: 99%

See 1 more Smart Citation

Drug-Loaded Biomimetic Carriers for Non-Hodgkin’s Lymphoma Therapy: Advances and Perspective

Li,

Zhang,

Wang

et al. 2024

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Chemotherapy remains the mainstay of treatment for the lymphoma patient population, despite its relatively poor therapeutic results, high toxicity, and low specificity. With the advancement of biotechnology, the significance of drugloading biomimetic materials in the medical field has become increasingly evident, attracting extensive attention from the scientific community and the pharmaceutical industry. Given that they can cater to the particular requirements of lymphoma patients, drug-loading biomimetic materials have recently become a potent and promising delivery approach for various applications. This review mainly reviews the recent advancements in the treatment of tumors with biological drug carrierloaded drugs, outlines the mechanisms of lymphoma development and the diverse treatment modalities currently available, and discusses the merits and limitations of biological drug carriers. What is more, the practical application of biocarriers in tumors is explored by providing examples, and the possibility of loading such organisms with antilymphoma drugs for the treatment of lymphoma is conceived.

show abstract

Section: Carrierssupporting

confidence: 53%

Section: Research Progress On Biological Drug Carriersmentioning

confidence: 99%

Drug-Loaded Biomimetic Carriers for Non-Hodgkin’s Lymphoma Therapy: Advances and Perspective

Li,

Zhang,

Wang

et al. 2024

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

“…Depending on the stability and potency of individual tumor-suppressing proteins, an advanced delivery system to improve half-life, targeting efficiency, bioavailability, and bioactivity needs to be developed. An example of an advanced formulation capable of high loading of proteins or peptides has recently been reported using flash nanoprecipitation 73 . Such systems can encapsulate proteins and peptides and also provide targeting ability towards a desired tumor/bone niche.…”

Section: Application Of Itscs CM and Protein Cocktailsmentioning

confidence: 99%

Three unconventional maxims in the natural selection of cancer cells: Generation of induced tumor-suppressing cells (iTSCs)

Li¹,

Huo²,

Li³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Induced tumor-suppressing cells (iTSCs) can be generated from cancer and non-cancer cells. Here, three paradoxical maxims for the action of iTSCs are reviewed: the secretion of tumor-suppressing proteins, their role as a “double-edged” sword, and the elimination of lesser-fit cancer cells. “Super-fit” cancer cells secrete an array of proteins, most of which contribute to enhancing their growth and removing “lesser-fit” cancer cells. These maxims explain the potential dilemma with therapeutic agents since the inhibitory agents tend to promote the synthesis of tumor-promoting proteins. The maxims suggest the possibility of a novel treatment option using cancer-guided evolutionary-fit iTSCs.

show abstract

“…Moreover, encapsulation in polymeric or liposomal formulations can assist with intracellular delivery of biologics such as genes and antimicrobial peptides, proteins and bacteriophages [115][116][117][118]. Prud'homme and colleagues have successfully used flash nanoprecipitation techniques to fabricate a number of nanoparticles of biologics including some with encapsulation efficiency being close to 100% [119]. However, in general issues arising from the use of organic solvents in encapsulated particle production, relatively low encapsulation efficiency, and further formulation as highly dispersible inhalation powders are yet to be resolved.…”

Section: Encapsulation In Micro and Nanoparticlesmentioning

confidence: 99%

Advancements in Particle Engineering for Inhalation Delivery of Small Molecules and Biotherapeutics

Chang

Chan

2022

Pharm Res

View full text Add to dashboard Cite

Dry powder inhalation formulations have become increasingly popular for local and systemic delivery of small molecules and biotherapeutics. Powder formulations provide distinct advantages over liquid formulations such as elimination of cold chain due to room temperature stability, improved portability, and the potential for increasing patient adherence. To become a viable product, it is essential to develop formulations that are stable (physically, chemically and/or biologically) and inhalable over the shelf-life. Physical particulate properties such as particle size, morphology and density, as well as chemical properties can significantly impact aerosol performance of the powder. This review will cover these critical attributes that can be engineered to enhance the dispersibility of inhalation powder formulations. Challenges in particle engineering for biotherapeutics will be assessed, followed by formulation strategies for overcoming the hurdles. Finally, the review will discuss recent examples of successful dry powder biotherapeutic formulations for inhalation delivery that have been clinically assessed.

show abstract

Highly-loaded protein nanocarriers prepared by Flash NanoPrecipitation with hydrophobic ion pairing

Cited by 9 publications

References 33 publications

Drug-Loaded Biomimetic Carriers for Non-Hodgkin’s Lymphoma Therapy: Advances and Perspective

Drug-Loaded Biomimetic Carriers for Non-Hodgkin’s Lymphoma Therapy: Advances and Perspective

Three unconventional maxims in the natural selection of cancer cells: Generation of induced tumor-suppressing cells (iTSCs)

Advancements in Particle Engineering for Inhalation Delivery of Small Molecules and Biotherapeutics

Contact Info

Product

Resources

About